Navigation Links
Baxter Announces Licensing Agreement for Innocoll's Gentamicin Surgical Implant in the United States
Date:8/25/2008

support a planned 2009 New Drug Application for U.S. regulatory approval.

"We look forward to making this product available for surgeons to help alleviate the burden of infections occurring from surgery. A gentamicin surgical implant complements Baxter's surgical portfolio of products for hemostasis and tissue sealing," said Ron Lloyd, vice president and general manager of Baxter's BioSurgery business.

Baxter is a global, diversified healthcare company with many specialty biologic products used in surgical settings for hemostasis, tissue sealing, tissue fixation and adhesion reduction. Innocoll, a privately held biopharmaceutical company, focuses on targeted biodegradable surgical implants and topical products to reduce infection.

"We are very pleased to announce this agreement with Baxter, a recognized market leader in specialty biologics," said Dr. Michael Myers, Innocoll chief executive officer. "We look forward to establishing a strong partnership with Baxter as we prepare for NDA filing and subsequent launch in the U.S. market."

Under the terms of the agreement, Baxter will pay a license fee and will make contingent clinical, regulatory and commercial milestone payments. Baxter will also contribute to the Phase III clinical costs and a portion of the registration fees. Innocoll will be responsible for the continued management of the clinical programs and the regulatory filing. Innocoll will manufacture and supply product to Baxter. In accordance with generally accepted accounting principles, Baxter expects to record a pre-tax charge of approximately $12 million for in-process research and development associated with this transaction in the third quarter of 2008.

About Innocoll, Inc.

Innocoll is a privately held, biopharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. It develops and manufactures a range of pharmaceutical products and medical devices using its propr
'/>"/>

SOURCE Baxter Healthcare Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Baxter Declares Quarterly Dividend
2. Baxter Raises Full-Year 2008 Outlook Following Strong Second-Quarter Financial Results
3. Bioniche Pharma Acquires Baxters ENLON(R) and ENLON-PLUS(R)
4. Baxters Board of Directors Declares Quarterly Dividend
5. Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook
6. Baxters V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals
7. Baxter Announces FDA Approval of ARTISS Slow-Setting Fibrin Sealant in Treatment of Burn Patients
8. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
9. Baxter and Its Foundation Contribute Nearly $53 Million in 2007 to Address Critical Needs Locally and Globally
10. Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products
11. Baxter Declares Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... MediVet America and NanoFiber Veterinary ... at the specialized Wolvega Horse Clinic. , Due to ... was ruptured 90% and her deep digital flexor tendon ... sentence for a horse. , The clinic has performed ... This revolutionary regenerative option for ruptured tendons has ...
(Date:9/19/2014)... simple. From crop yields to disease risks, the biological ... "complex traits." Just as for heightthe textbook example of ... disease are shaped by multiple genetic and environmental influences, ... track down such genes, geneticists typically mate two individuals ... and a small mouseand then study their descendents, looking ...
(Date:9/19/2014)... to move data would consume much less power ... as chips, transistor counts rise. , Of the ... emitters, modulators, and detectors emitters are the ... optical chips is molybdenum disulfide (MoS2), which has ... atom-thick layer. Other experimental on-chip light emitters have ...
(Date:9/19/2014)... 19, 2014  An entire month is dedicated to ... – Charcot-Marie-Tooth disease (CMT) – a debilitating neuromuscular disease ... muscle atrophy, weakness, and foot and hand deformities. CMT ... worldwide. CMT is a progressive disease, and over time ... mobility devices such as leg braces, wheelchairs and scooters ...
Breaking Biology Technology:World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3Want to link genes to complex traits? Start with more diversity 2Toward optical chips 2Toward optical chips 3September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2
... Md., Sept. 2 Micromet, Inc.,(Nasdaq: MITI ... novel, proprietary antibodies for the treatment of cancer,inflammation ... A. Phillips as Senior Vice President and Chief ... of the Company,s board of directors,since 2000, and ...
... a New Jersey-based,leading provider of prescription co-pay programs ... significantly expanded the scope of,the lawsuit that it ... the State,of New York, County of New York, ... of McKesson Corporation. PSKW is,now seeking, in addition ...
... The BEAUTIFUL study: a step further in title ... BEAUTIFUL study: efficacy of session title ivabradine in reduction of cardiovascular ... among patients with stable coronary ... dysfunction, ESC Hotline ...
Cached Biology Technology:Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 2Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 3Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 4PSKW Expands Its Lawsuit Against McKesson to Seek Assignment of McKesson's Patent Application 2With the BEAUTIFUL Results, Procoralan* (ivabradine) is the First Antianginal Treatment Shown to Reduce Myocardial Infarction (Heart Attack) and Revascularisation in Stable Coronary Patients 2With the BEAUTIFUL Results, Procoralan* (ivabradine) is the First Antianginal Treatment Shown to Reduce Myocardial Infarction (Heart Attack) and Revascularisation in Stable Coronary Patients 3
(Date:9/18/2014)... have developed a unique method to use microbes buried ... areas. , The first microbe-powered, self-sustaining wastewater treatment ... to clean up waste from large farming operations and ... Professor Haluk Beyenal and graduate student Timothy Ewing in ... system in the online edition of Journal of ...
(Date:9/18/2014)... 18, 2014 New research into the Crimean-Congo hemorrhagic ... severe hemorrhagic disease in humans similar to that caused ... CCHFV infection. This discovery has the potential to lead ... , The research, reported in a paper ... and conducted by scientists at the Texas Biomedical Research ...
(Date:9/18/2014)... how many times it,s demonstrated, it,s still hard ... , But by using a signaling system called ... behavior to suit their population. In short, some ... and act accordingly. , Once the population of ... from innocuous to pathogenic, or from unhelpful to ...
Breaking Biology News(10 mins):Researchers develop unique waste cleanup for rural areas 2Research milestone in CCHF virus could help identify new treatments 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3
... have come up with a new twist in their efforts ... DNA genetic code. They have developed the first, versatile DNA ... key to unlocking the vital code behind human heredity and ... director of the Biodesign Institute,s Center for Single Molecule Biophysics, ...
... 2010) For years, doctors have warned patients to finish ... "superbug" that can mount a more powerful defense against the ... engineers indicates that treating bacteria with levels of antibiotics insufficient ... wide range of antibiotics. In the Feb. 12 issue ...
... help save the sight of patients with a type of ... University of Leeds found that the TSPAN12 gene is faulty ... Vitreoretinopathy), which affects the development of the eye. While ... of the same family may carry the faulty gene without ...
Cached Biology News:ASU scientists develop universal DNA reader to advance faster, cheaper sequencing efforts 2ASU scientists develop universal DNA reader to advance faster, cheaper sequencing efforts 3Low levels of antibiotics cause multidrug resistance in 'superbugs' 2Low levels of antibiotics cause multidrug resistance in 'superbugs' 3New gene discovery could help to prevent blindness 2
... Ambions 96 well Magnetic-Ring Stand is ... 96 well U-bottom microplates. The stand has ... 96 well microtiter plate footprint. The use ... enables fast and easy magnetic separation. With ...
... from Thermus aquaticus expressed in E. coli; ... of 250 units enzyme/tube and Buffer I ... the same enzyme as AmpliTaq DNA Polymerase ... separation process to ensure that contaminating bacterial ...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2...
... is a versatile and easy-to use enzyme, ... GCpro Taq DNA Polymerase is prepared from ... containing the DNA polymerase I gene from ... processive 5'-3' DNA polymerase activity. Its inherent ...
Biology Products: